Influence of preoperative chemoradiotherapy on changes of epidermal growth factor receptor expression in patients treated by preoperative chemoradiotherapy for local advanced rectal carcinoma
The aim of this retrospective study was to determine the prognostic impact of expression of epidermal growth factor receptor (EGFR) changes during neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma. One hundred and three patients with locally advanced rectal adenoc...
Gespeichert in:
| Veröffentlicht in: | Klinická onkologie 2014, Vol.27 (5), p.361-366 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | cze ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 366 |
|---|---|
| container_issue | 5 |
| container_start_page | 361 |
| container_title | Klinická onkologie |
| container_volume | 27 |
| creator | Richter, I Dvořák, J Blüml, A Cermáková, E Bartoš, J Urbanec, M Sitorová, V Ryška, A Sirák, I Buka, D Ferko, A Melichar, B Petera, J |
| description | The aim of this retrospective study was to determine the prognostic impact of expression of epidermal growth factor receptor (EGFR) changes during neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma.
One hundred and three patients with locally advanced rectal adenocarcinoma of stage II and III were evaluated. All patients were administered the total dose of 44 -- 50.4 Gy. Concomitantly, the patients received capecitabine in the dose 825 mg/ m² in two daily oral administrations or 5- fluorouracil in the dose 200 mg/ m² in continuous infusion. Surgery was indicated at intervals of 4-8 weeks from chemoradiotherapy completion. EGFR expression in the pretreatment biopsies and in resected specimens was assessed with immunohistochemistry.
All of 103 patients received radiotherapy without interruption up to the total planned dose. Downstaging was described in 64 patients. Six patients had complete pathologic remission. Recurrence occurred in 49 patients. Local recurrence was found in 22 patients, generalization of disease was reported in 27 patients. A total of 51 patients died. Increased EGFR expression was found in 26 patients. The statistically significantly shorter overall survival (p < 0.001) and disease-free survival (p < 0.001) was found in patients with increased expression of EGFR compared with patients where no increase in the expression of EGFR was observed during neoadjuvant chemoradiotherapy.
The overexpression of EGFR during neoadjuvant chemoradiotherapy for locally advanced rectal adenocarcinoma is associated with significant shorter overall survival and disease-free survival. |
| doi_str_mv | 10.14735/amko2014361 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1612290297</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1612290297</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1311-83394828c17f608b25e22232cf8ccba97a658419fb99a784d00dc750fcfbbce83</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhq0KRFelN87Ixx4I-COOnSOqSqlUiQtI3KLJZNxNSeJgewv76_rX8NIPccMXe0aPnxnpZeyNFO9lbbX5APOPoISsdSOP2EY6oSqjhX3BNsI1qqpb8_2YnaZ0K8pplDXGvWLHymiprKw37P5q8dOOFiQePF8jhZUi5PGOOG5pDhGGMeRt6a17HpbShOWG0gGmdRwozjDxmxh-5S33gDlEHglpPTzod_GlNJZv48LXYqUlJ54jQaaB9_v_zfNFMgUsE2C4g7LjcJDnUiNEHJcww2v20sOU6PTxPmHfPl18Pf9cXX-5vDr_eF2h1FJWTuu2dsqhtL4RrleGlFJaoXeIPbQWGuNq2fq-bcG6ehBiQGuER9_3SE6fsLMH7xrDzx2l3M1jQpomWCjsUicbqVQrVGsL-u4BxRhSiuS7NY4zxH0nRfc3te6f1Ar-9tG862canuGnjPQfYKeZKQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1612290297</pqid></control><display><type>article</type><title>Influence of preoperative chemoradiotherapy on changes of epidermal growth factor receptor expression in patients treated by preoperative chemoradiotherapy for local advanced rectal carcinoma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Richter, I ; Dvořák, J ; Blüml, A ; Cermáková, E ; Bartoš, J ; Urbanec, M ; Sitorová, V ; Ryška, A ; Sirák, I ; Buka, D ; Ferko, A ; Melichar, B ; Petera, J</creator><creatorcontrib>Richter, I ; Dvořák, J ; Blüml, A ; Cermáková, E ; Bartoš, J ; Urbanec, M ; Sitorová, V ; Ryška, A ; Sirák, I ; Buka, D ; Ferko, A ; Melichar, B ; Petera, J</creatorcontrib><description>The aim of this retrospective study was to determine the prognostic impact of expression of epidermal growth factor receptor (EGFR) changes during neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma.
One hundred and three patients with locally advanced rectal adenocarcinoma of stage II and III were evaluated. All patients were administered the total dose of 44 -- 50.4 Gy. Concomitantly, the patients received capecitabine in the dose 825 mg/ m² in two daily oral administrations or 5- fluorouracil in the dose 200 mg/ m² in continuous infusion. Surgery was indicated at intervals of 4-8 weeks from chemoradiotherapy completion. EGFR expression in the pretreatment biopsies and in resected specimens was assessed with immunohistochemistry.
All of 103 patients received radiotherapy without interruption up to the total planned dose. Downstaging was described in 64 patients. Six patients had complete pathologic remission. Recurrence occurred in 49 patients. Local recurrence was found in 22 patients, generalization of disease was reported in 27 patients. A total of 51 patients died. Increased EGFR expression was found in 26 patients. The statistically significantly shorter overall survival (p < 0.001) and disease-free survival (p < 0.001) was found in patients with increased expression of EGFR compared with patients where no increase in the expression of EGFR was observed during neoadjuvant chemoradiotherapy.
The overexpression of EGFR during neoadjuvant chemoradiotherapy for locally advanced rectal adenocarcinoma is associated with significant shorter overall survival and disease-free survival.</description><identifier>ISSN: 0862-495X</identifier><identifier>EISSN: 1802-5307</identifier><identifier>DOI: 10.14735/amko2014361</identifier><identifier>PMID: 25312714</identifier><language>cze ; eng</language><publisher>Czech Republic</publisher><subject>Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma - therapy ; Adult ; Aged ; Antimetabolites, Antineoplastic - therapeutic use ; Capecitabine ; Chemoradiotherapy, Adjuvant - methods ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - analogs & derivatives ; Humans ; Male ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Recurrence, Local - metabolism ; Neoplasm Recurrence, Local - mortality ; Preoperative Care ; Prognosis ; Radiotherapy Dosage ; Receptor, Epidermal Growth Factor - metabolism ; Rectal Neoplasms - mortality ; Rectal Neoplasms - pathology ; Rectal Neoplasms - therapy ; Retrospective Studies</subject><ispartof>Klinická onkologie, 2014, Vol.27 (5), p.361-366</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25312714$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Richter, I</creatorcontrib><creatorcontrib>Dvořák, J</creatorcontrib><creatorcontrib>Blüml, A</creatorcontrib><creatorcontrib>Cermáková, E</creatorcontrib><creatorcontrib>Bartoš, J</creatorcontrib><creatorcontrib>Urbanec, M</creatorcontrib><creatorcontrib>Sitorová, V</creatorcontrib><creatorcontrib>Ryška, A</creatorcontrib><creatorcontrib>Sirák, I</creatorcontrib><creatorcontrib>Buka, D</creatorcontrib><creatorcontrib>Ferko, A</creatorcontrib><creatorcontrib>Melichar, B</creatorcontrib><creatorcontrib>Petera, J</creatorcontrib><title>Influence of preoperative chemoradiotherapy on changes of epidermal growth factor receptor expression in patients treated by preoperative chemoradiotherapy for local advanced rectal carcinoma</title><title>Klinická onkologie</title><addtitle>Klin Onkol</addtitle><description>The aim of this retrospective study was to determine the prognostic impact of expression of epidermal growth factor receptor (EGFR) changes during neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma.
One hundred and three patients with locally advanced rectal adenocarcinoma of stage II and III were evaluated. All patients were administered the total dose of 44 -- 50.4 Gy. Concomitantly, the patients received capecitabine in the dose 825 mg/ m² in two daily oral administrations or 5- fluorouracil in the dose 200 mg/ m² in continuous infusion. Surgery was indicated at intervals of 4-8 weeks from chemoradiotherapy completion. EGFR expression in the pretreatment biopsies and in resected specimens was assessed with immunohistochemistry.
All of 103 patients received radiotherapy without interruption up to the total planned dose. Downstaging was described in 64 patients. Six patients had complete pathologic remission. Recurrence occurred in 49 patients. Local recurrence was found in 22 patients, generalization of disease was reported in 27 patients. A total of 51 patients died. Increased EGFR expression was found in 26 patients. The statistically significantly shorter overall survival (p < 0.001) and disease-free survival (p < 0.001) was found in patients with increased expression of EGFR compared with patients where no increase in the expression of EGFR was observed during neoadjuvant chemoradiotherapy.
The overexpression of EGFR during neoadjuvant chemoradiotherapy for locally advanced rectal adenocarcinoma is associated with significant shorter overall survival and disease-free survival.</description><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - therapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Capecitabine</subject><subject>Chemoradiotherapy, Adjuvant - methods</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Disease-Free Survival</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - analogs & derivatives</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Recurrence, Local - metabolism</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Preoperative Care</subject><subject>Prognosis</subject><subject>Radiotherapy Dosage</subject><subject>Receptor, Epidermal Growth Factor - metabolism</subject><subject>Rectal Neoplasms - mortality</subject><subject>Rectal Neoplasms - pathology</subject><subject>Rectal Neoplasms - therapy</subject><subject>Retrospective Studies</subject><issn>0862-495X</issn><issn>1802-5307</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhq0KRFelN87Ixx4I-COOnSOqSqlUiQtI3KLJZNxNSeJgewv76_rX8NIPccMXe0aPnxnpZeyNFO9lbbX5APOPoISsdSOP2EY6oSqjhX3BNsI1qqpb8_2YnaZ0K8pplDXGvWLHymiprKw37P5q8dOOFiQePF8jhZUi5PGOOG5pDhGGMeRt6a17HpbShOWG0gGmdRwozjDxmxh-5S33gDlEHglpPTzod_GlNJZv48LXYqUlJ54jQaaB9_v_zfNFMgUsE2C4g7LjcJDnUiNEHJcww2v20sOU6PTxPmHfPl18Pf9cXX-5vDr_eF2h1FJWTuu2dsqhtL4RrleGlFJaoXeIPbQWGuNq2fq-bcG6ehBiQGuER9_3SE6fsLMH7xrDzx2l3M1jQpomWCjsUicbqVQrVGsL-u4BxRhSiuS7NY4zxH0nRfc3te6f1Ar-9tG862canuGnjPQfYKeZKQ</recordid><startdate>2014</startdate><enddate>2014</enddate><creator>Richter, I</creator><creator>Dvořák, J</creator><creator>Blüml, A</creator><creator>Cermáková, E</creator><creator>Bartoš, J</creator><creator>Urbanec, M</creator><creator>Sitorová, V</creator><creator>Ryška, A</creator><creator>Sirák, I</creator><creator>Buka, D</creator><creator>Ferko, A</creator><creator>Melichar, B</creator><creator>Petera, J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2014</creationdate><title>Influence of preoperative chemoradiotherapy on changes of epidermal growth factor receptor expression in patients treated by preoperative chemoradiotherapy for local advanced rectal carcinoma</title><author>Richter, I ; Dvořák, J ; Blüml, A ; Cermáková, E ; Bartoš, J ; Urbanec, M ; Sitorová, V ; Ryška, A ; Sirák, I ; Buka, D ; Ferko, A ; Melichar, B ; Petera, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1311-83394828c17f608b25e22232cf8ccba97a658419fb99a784d00dc750fcfbbce83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>cze ; eng</language><creationdate>2014</creationdate><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - therapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Capecitabine</topic><topic>Chemoradiotherapy, Adjuvant - methods</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Disease-Free Survival</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - analogs & derivatives</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Recurrence, Local - metabolism</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Preoperative Care</topic><topic>Prognosis</topic><topic>Radiotherapy Dosage</topic><topic>Receptor, Epidermal Growth Factor - metabolism</topic><topic>Rectal Neoplasms - mortality</topic><topic>Rectal Neoplasms - pathology</topic><topic>Rectal Neoplasms - therapy</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Richter, I</creatorcontrib><creatorcontrib>Dvořák, J</creatorcontrib><creatorcontrib>Blüml, A</creatorcontrib><creatorcontrib>Cermáková, E</creatorcontrib><creatorcontrib>Bartoš, J</creatorcontrib><creatorcontrib>Urbanec, M</creatorcontrib><creatorcontrib>Sitorová, V</creatorcontrib><creatorcontrib>Ryška, A</creatorcontrib><creatorcontrib>Sirák, I</creatorcontrib><creatorcontrib>Buka, D</creatorcontrib><creatorcontrib>Ferko, A</creatorcontrib><creatorcontrib>Melichar, B</creatorcontrib><creatorcontrib>Petera, J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Klinická onkologie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Richter, I</au><au>Dvořák, J</au><au>Blüml, A</au><au>Cermáková, E</au><au>Bartoš, J</au><au>Urbanec, M</au><au>Sitorová, V</au><au>Ryška, A</au><au>Sirák, I</au><au>Buka, D</au><au>Ferko, A</au><au>Melichar, B</au><au>Petera, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of preoperative chemoradiotherapy on changes of epidermal growth factor receptor expression in patients treated by preoperative chemoradiotherapy for local advanced rectal carcinoma</atitle><jtitle>Klinická onkologie</jtitle><addtitle>Klin Onkol</addtitle><date>2014</date><risdate>2014</risdate><volume>27</volume><issue>5</issue><spage>361</spage><epage>366</epage><pages>361-366</pages><issn>0862-495X</issn><eissn>1802-5307</eissn><abstract>The aim of this retrospective study was to determine the prognostic impact of expression of epidermal growth factor receptor (EGFR) changes during neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma.
One hundred and three patients with locally advanced rectal adenocarcinoma of stage II and III were evaluated. All patients were administered the total dose of 44 -- 50.4 Gy. Concomitantly, the patients received capecitabine in the dose 825 mg/ m² in two daily oral administrations or 5- fluorouracil in the dose 200 mg/ m² in continuous infusion. Surgery was indicated at intervals of 4-8 weeks from chemoradiotherapy completion. EGFR expression in the pretreatment biopsies and in resected specimens was assessed with immunohistochemistry.
All of 103 patients received radiotherapy without interruption up to the total planned dose. Downstaging was described in 64 patients. Six patients had complete pathologic remission. Recurrence occurred in 49 patients. Local recurrence was found in 22 patients, generalization of disease was reported in 27 patients. A total of 51 patients died. Increased EGFR expression was found in 26 patients. The statistically significantly shorter overall survival (p < 0.001) and disease-free survival (p < 0.001) was found in patients with increased expression of EGFR compared with patients where no increase in the expression of EGFR was observed during neoadjuvant chemoradiotherapy.
The overexpression of EGFR during neoadjuvant chemoradiotherapy for locally advanced rectal adenocarcinoma is associated with significant shorter overall survival and disease-free survival.</abstract><cop>Czech Republic</cop><pmid>25312714</pmid><doi>10.14735/amko2014361</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0862-495X |
| ispartof | Klinická onkologie, 2014, Vol.27 (5), p.361-366 |
| issn | 0862-495X 1802-5307 |
| language | cze ; eng |
| recordid | cdi_proquest_miscellaneous_1612290297 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - therapy Adult Aged Antimetabolites, Antineoplastic - therapeutic use Capecitabine Chemoradiotherapy, Adjuvant - methods Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Disease-Free Survival Drug Administration Schedule Female Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives Humans Male Middle Aged Neoadjuvant Therapy Neoplasm Recurrence, Local - metabolism Neoplasm Recurrence, Local - mortality Preoperative Care Prognosis Radiotherapy Dosage Receptor, Epidermal Growth Factor - metabolism Rectal Neoplasms - mortality Rectal Neoplasms - pathology Rectal Neoplasms - therapy Retrospective Studies |
| title | Influence of preoperative chemoradiotherapy on changes of epidermal growth factor receptor expression in patients treated by preoperative chemoradiotherapy for local advanced rectal carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T04%3A05%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20preoperative%20chemoradiotherapy%20on%20changes%20of%20epidermal%20growth%20factor%20receptor%20expression%20in%20patients%20treated%20by%20preoperative%20chemoradiotherapy%20for%20local%20advanced%20rectal%20carcinoma&rft.jtitle=Klinick%C3%A1%20onkologie&rft.au=Richter,%20I&rft.date=2014&rft.volume=27&rft.issue=5&rft.spage=361&rft.epage=366&rft.pages=361-366&rft.issn=0862-495X&rft.eissn=1802-5307&rft_id=info:doi/10.14735/amko2014361&rft_dat=%3Cproquest_cross%3E1612290297%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1612290297&rft_id=info:pmid/25312714&rfr_iscdi=true |